Table 4.
Drug resistance and mutations of the individuals with ART failure in this study.
| Antiretroviral Drug | Number | % (N2 = 164) | HIV drug resistance mutations (n, %) |
|---|---|---|---|
| Total | 83 | 50.6 | |
| PIs | 6 | 3.7 | Q58E (5, 3.0), M46L (1, 0.6) |
| NFV | 1 | 0.6 | |
| TPV/r | 5 | 3.0 | |
| NRTIs | 52 | 31.7 | M184I/V (49, 29.9), T215Y/F (10, 6.1), M41L (9, 5.5), D67N (9, 5.5), K65R (13, 7.9), K70R/T/E/G/Q (12, 7.3), Y115F (7, 4.3), L74I/V (3, 1.8), L210W (2,1.2) |
| ABC | 52 | 31.7 | |
| AZT | 12 | 7.3 | |
| D4T | 28 | 17.1 | |
| DDI | 35 | 21.3 | |
| FTC | 52 | 31.7 | |
| 3TC | 52 | 31.7 | |
| TDF | 25 | 15.2 | |
| Drug resistance ≥3 | 52 | 31.7 | |
| NNRTIs | 76 | 46.3 | K103N (35,21.3), E138A/G/Q (3, 1.8), V179E (22, 13.4), V106I/M (16, 9.8), K101E/Q/H/P/T (11, 6.7), G190A/S (12, 7.3), A98G (3, 1.8), V108I (6, 3.7), P225H (5, 3.0), Y181C (7, 4.3), F227L (9, 5.5), Y188L/C (6, 3.7) |
| DOR | 37 | 22.6 | |
| EFV | 73 | 44.5 | |
| ETR | 22 | 13.4 | |
| NVP | 73 | 44.5 | |
| RPV | 32 | 19.5 | |
| Drug resistance ≥3 | 43 | 26.2 |